« Previous Next » International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1305-1313 , April 2010

Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

Lawrence B. Marks, M.D.
- Radiation Oncology, University of North Carolina, Chapel Hill, NC
- Department of Radiation Oncology, Duke University, Durham, NC
- Reprint requests to: Lawrence B. Marks, M.D., Department of Radiation Oncology, University of North Carolina School of Medicine, CB #7512, Chapel Hill, NC 27599-7512. Tel: (919) 966-0400; Fax: (919) 966-7681
Constance Cirrincione, M.S.
- Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC
Thomas J. Fitzgerald, M.D.
- Department of Radiation Oncology, University of Massachusetts, Worcester, MA
- Quality Assurance Review Center, Providence, RI
Frances Laurie
- Quality Assurance Review Center, Providence, RI
Arvin S. Glicksman, M.D.
- Quality Assurance Review Center, Providence, RI
- Rhode Island Cancer Council, Pawtucket, RI
James Vredenburgh, M.D.
- Department of Medical Oncology, Duke University, Durham, NC
Leonard R. Prosnitz, M.D.
- Department of Radiation Oncology, Duke University, Durham, NC
Elizabeth J. Shpall, M.D.
- Adult Bone Marrow Transplant Program, University of Colorado, Denver, CO
Michael Crump, M.D.
- Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
Paul G. Richardson, M.D.
- Dana Farber Cancer Institute, Boston, MA
Michael W. Schuster, M.D.
- North Shore–Long Island Jewish Medical Center, Manhasset, NY
Jinli Ma, M.D.
- Department of Radiation Oncology, Duke University, Durham, NC
- Department of Radiation Oncology, Fudan University Cancer Hospital, Shanghai, China
Bercedis L. Peterson, Ph.D.
- Cancer and Leukemia Group B Statistical Center, Duke University, Durham, NC
Larry Norton, M.D.
- Department of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
Steven Seagren, M.D.
- Department of Radiation Oncology, University of California at San Diego, San Diego, CA
I. Craig Henderson, M.D.
- University of California at San Francisco (UCSF) Cancer Center, UCSF, San Francisco, CA
David D. Hurd, M.D.
- Departments of Hematology and Oncology, Wake Forest University, Winston-Salem, NC
William P. Peters, M.D.
- Karmanos Cancer Institute, Wayne State University, Detroit, MI
Cancer and Leukemia Group B, Southwest Oncology Group, and National Cancer Institute of Canada Clinical Trials Group

Received 21 August 2008 ,Revised 3 March 2009 ,Accepted 4 April 2009.

To access this article, please choose from the options below

Supported by National Cancer Institute (NCI) Grants CA31946 (to Cancer and Leukemia Group B [CALBG], Richard L. Schilsky, Chairman), CA33601 (to the CALGB Statistical Center, Stephen George, Director), CA29511 (to the Quality Assurance Review Center), CA47577 (to J.V. and L.R.P.), CA42777 (to E.J.S.), CA77202 (to M.C.), CA32291 (to P.G.R.), CA35279 (to M.W.S.), CA77651 (to L.N.), CA11789 (to S.S.), CA60138 (to I.C.H.), CA03927 (to D.D.H.), and CA14028 (to W.P.P.). This manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NCI.

Conflict of interest: L.B.M. receives honoraria from Varian Medical Systems, and grants from the National Institutes of Health, the Lance Armstrong Foundation, and the U.S. Department of Defense. P.G.R. receives an honorarium from Millennium Pharmaceuticals.

PII: S0360-3016(09)00575-6

doi: 10.1016/j.ijrobp.2009.04.013

« Previous Next » International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1305-1313 , April 2010